CENTESSA PHARMACEUTICALS-ADR
CNTANASDAQ🏆 #1102 by market capUS Equity
$40.50▲ $0.00 (+0.00%)
Live1h—
24h▲ 0.0%
7d▼ 0.1%
14d▼ 0.1%
30d▼ 0.1%
1y▲ 136.3%
🏦Market Cap
$6.27B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
66
Fair
📊
Analyst Ratings
Price
$40.50
Total
14
Raised
1
Lowered
5
Avg PT
$41.00
H / L
$42 / $40
| Institution | Action | Rating | Date |
|---|---|---|---|
Wells Fargo | Downgraded | Overweight → Equal Weight | 2026-04-20 |
Guggenheim | Downgraded | Buy → Neutral | 2026-04-02 |
Leerink Partners | Downgraded | Outperform → Market Perform | 2026-04-01 |
Needham | Downgraded | Buy → Hold | 2026-03-31 |
Wolfe Research | Downgraded | Outperform → Peer Perform | 2026-03-31 |
Truist Securities | Reiterated | Buy | 2026-01-29 |
Chardan Capital | Reiterated | Buy | 2026-01-02 |
Oppenheimer | Reiterated | Outperform | 2025-12-10 |
B. Riley Securities | Reiterated | Buy | 2025-12-01 |
Morgan Stanley | Upgraded | Equal Weight → Overweight | 2024-09-19 |
BMO Capital | Reiterated | Outperform | 2024-09-16 |
Jefferies | Reiterated | Buy | 2024-09-11 |
Goldman Sachs | Reiterated | Neutral | 2023-08-15 |
SVB Securities | Reiterated | Outperform | 2023-08-15 |
One row per institution, most recent rating